Certain key clinical characteristics in patients with severe asthma may help clinicians ID those who may benefit from additional targeted drug therapy, such as benralizumab.
[maxbutton id=”1″ url=”http://info.rtmagazine.com/regform” text=”SUBSCRIBE TO NEWS” ]
After a 12-month follow-up period, patients who were eligible to receive benralizumab had greater mean incidences of asthma exacerbations (3.9/year vs 2.2/year), and asthma-related hospitalizations (0.19/year vs 0.09/year) compared with patients who were not eligible for benralizumab. In addition, the percentage of patients who were eligible for treatment visited the emergency department more often than patients who were ineligible for treatment (40% vs 25%).
A better understanding of the clinical characteristics of patients who are eligible for benralizumab can help clinicians better identify positive responders among patients with severe asthma and eosinophilia.